Table 2 Sensitivity and specificity of unfavorable subsets for each tumor marker

SCC, n (%)

 ≤ 1.5 ng/ml

8 (67)

63 (81)

0.65

15%

80%

 > 1.5 ng/ml

2 (17)

11 (14)

NA

2 (17)

4 (5)

-

-

CYFRA, n (%)

 ≤ 2.2 ng/ml

5 (42)

23 (30)

0.29

69%

50%

 > 2.2 ng/ml

5 (42)

52 (67)

NA

2 (17)

3 (4)

-

-

CEA, n (%)

 ≤ 5.0 ng/ml

10 (83)

46 (59)

0.12

41%

83%

 > 5.0 ng/ml

2 (17)

32 (41)

SLeX, n (%)

 ≤ 38.0 U/ml

6 (50)

49 (63)

1.0

34%

67%

 > 38.0 U/ml

3 (25)

25 (32)

NA

3 (25)

4 (5)

-

-

NSE, n (%)

 ≤ 15.0 ng/ml

8 (67)

41 (53)

0.18

45%

80%

 > 15.0 ng/ml

2 (17)

33 (42)

NA

2 (17)

4 (5)

-

-

Pro-GRP, n (%)

 < 81.0 pg/ml

9 (75)

66 (85)

1.0

11%

90%

 ≥ 81.0 pg/ml

1 (8)

8 (10)

NA

2 (17)

4 (5)

-

-

AFP, n (%)

 ≤ 10.0 ng/ml

8 (67)

68 (87)

0.24

8%

80%

 > 10.0 ng/ml

2 (17)

6 (8)

NA

2 (17)

4 (5)

-

-

PIVKA-II, n (%)

 < 40 mAU/ml

10 (83)

70 (90)

1.0

4%

100%

 ≥ 40 mAU/ml

0

3 (4)

NA

2 (17)

5 (6)

-

-

PSA, n (%)

 ≤ 2.7 ng/ml

3 (25)

29 (37)

1.0

22%

100%

 > 2.7 ng/ml

0

8 (10)

NA

9 (75)

41 (53)

-

-

sIL-2R, n (%)

 ≤ 587 U/ml

0

3 (4)

-

40%

-

 > 587 U/ml

0

2 (3)

NA

12 (100)

73 (94)

-

-

CA19-9, n (%)

 ≤ 37 U/ml

8 (67)

56 (72)

1.0

27%

80%

 > 37 U/ml

2 (17)

21 (27)

NA

2 (17)

1 (1)

-

-

CA125, n (%)

 ≤ 35 U/ml

6 (50)

26 (33)

0.32

63%

55%

 > 35 U/ml

5 (42)

45 (58)

NA

1 (8)

7 (9)

-

-

CA15-3, n (%)

 ≤ 28 U/ml

9 (75)

40 (51)

0.22

46%

75%

 > 28 U/ml

3 (25)

34 (44)

NA

0

4 (5)

-

-

ST439, n (%)

 ≤ 4.5 U/ml

11 (92)

50 (64)

0.03

32%

100%

 > 4.5 U/ml

0

24 (31)

NA

1 (8)

4 (5)

-

-

elastase-1, n (%)

 ≤ 300 ng/dl

10 (83)

68 (87)

1.0

7%

100%

 > 300 ng/dl

0

5 (6)

NA

2 (17)

5 (6)

-

-

hCG, n (%)

 ≤ 3.0 mIU/ml

8 (67)

64 (82)

0.62

12%

80%

 > 3.0 mIU/ml

2 (17)

9 (12)

NA

2 (17)

5 (6)

-

-

STN, n (%)

 ≤ 45.0 U/ml

8 (67)

46 (59)

0.049

36%

100%

 > 45.0 U/ml

0

26 (33)

NA

4 (33)

6 (8)

-

-